Longer-term follow-up of patients with refractory and relapsed diffuse large B-cell lymphoma (DLBCL) who received chimeric antigen receptor (CAR) T cell therapy showed sustained responses in about half of the patients, suggesting that CAR-T therapy may be an effective option for this hard-to-treat non-Hodgkin's lymphoma, according to the ZUMA-1* and JULIET** trials presented at ASH 2017.
Combining aspirin with warfarin led to increased bleeding complications in patients with atrial fibrillation (AF) or venous thromboembolic disease (VTE) compared with warfarin alone, resulting in higher rates of major bleeding events and hospital admissions, according to data presented at ASH 2017.
Defibrotide treatment may be beneficial to adult patients with posthematopoietic stem cell transplantation (HSCT) hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), reports a new study presented at the concluded 59th American Society of Haematology Annual Meeting (ASH 2017).
Use of idelalisib plus ofatumumab in the frontline treatment of chronic lymphocytic leukaemia (CLL) is effective, yielding high overall response rate, although this is counterbalanced by significant toxicities, according to efficacy data from a phase II trial.
In the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (CML), patients presenting BCR-ABL1 transcript levels ≤10 percent at 3 months are more likely to achieve major molecular response at 12 months with faster response rate compared with those who have transcript levels >10 percent, according to ≥12 months of follow-up data from the BFORE* trial.
Treatment with defibrotide is safe and effective for patients with veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), following either allogeneic or autologous haematopoietic stem cell transplant (HSCT), according to the results of a study presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition in Atlanta, Georgia.
Once-weekly subcutaneous administration of the bispecific humanized monoclonal antibody emicizumab successfully prevented or reduced bleeds with a favourable safety profile in paediatric patients with haemophilia A with inhibitors in the phase III HAVEN-2* trial, confirming the findings of a previous interim analysis.
Platelet count thresholds <20 x 109/L and <10 x 109/L are associated with major increased risk for both any and mucosal bleeding. Furthermore, platelet count, female sex and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) are risk factors for the risk of any bleeding, according to a study presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia.
In newly diagnosed, transplant-eligible multiple myeloma (MM) patients, induction therapy with cyclophosphamide-bortezomib-dexamethasone (CyBorD) delivers a comparable efficacy to bortezomib-dexamethasone (Vel-Dex), according to a new study presented at the recently concluded 59th American Society of Hematology Annual Meeting (ASH 2017).
Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.